Conversion to rapamycin immunosuppression for malignancy after kidney transplantation

Area of Science:

• Nephrology
• Oncology
• Immunosuppression

Background:

• Malignancies are a significant cause of morbidity and mortality in kidney transplant recipients due to immunosuppressive therapy.
• Rapamycin demonstrates potential in limiting the proliferation of various malignant cell lines.

Purpose of the Study:

• To evaluate the efficacy of switching to rapamycin-based immunosuppression in renal transplant recipients who developed malignancies.
• To assess the impact of rapamycin on tumor regression and graft function in this patient population.

Main Methods:

• Fifteen kidney transplant recipients diagnosed with various malignancies were switched from calcineurin inhibitor-based immunosuppression to rapamycin.
• Rapamycin was used as monotherapy, or in combination with steroids or mycophenolate mofetil.
• Patients were monitored for tumor response, graft function, and overall survival.

Main Results:

• Eleven out of fifteen patients achieved cancer remission at a mean follow-up of 32.7 months.
• Renal graft function remained stable in most patients throughout the follow-up period.
• Two patients with metastatic cancer and two with post-transplant lymphoproliferative disorder (PTLD) did not survive.

Conclusions:

• Rapamycin-based immunosuppression may facilitate tumor regression in non-metastatic cancers post-kidney transplantation.
• The observed tumor regression could be attributed to rapamycin or the overall reduction in immunosuppression.
• Further research is needed to definitively establish the role of rapamycin in cancer regression.